NAUT Stock Forecast: Nautilus Biotechnology, Inc. Price Predictions for 2026-2027
The median 12-month analyst price target for Nautilus Biotechnology, Inc. is $4. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 70 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Nautilus Biotechnology, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (84): Analysts have, on balance, been raising their forecasts.
Quality (20): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
NAUT stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on NAUT, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 29 Sept 2026 | Roth Capital | Initiates | Buy | $3.50 |
| 9 Sept 2026 | Leerink Partners | Initiates | Outperform | $4.00 |
| 27 Feb 2026 | Guggenheim | Maintains | Buy | $2.50 → $4.00 |
| 5 Dec 2024 | Goldman Sachs | Downgrade | Sell | — |
| 27 June 2024 | Guggenheim | Initiates | Buy | — |
| 3 June 2024 | Jefferies | Assumes | Hold | $5.00 → $3.00 |
| 3 Aug 2023 | Morgan Stanley | Reiterates | Equal-Weight | — |
| 3 Aug 2022 | Goldman Sachs | Maintains | Neutral | — |
| 3 Aug 2022 | Morgan Stanley | Maintains | Equal-Weight | — |
| 14 July 2022 | Goldman Sachs | Maintains | Neutral | — |
| 13 Apr 2022 | Goldman Sachs | Maintains | Neutral | — |
| 6 Jan 2022 | Morgan Stanley | Initiates | Equal-Weight | — |
| 2 Nov 2021 | Cowen & Co. | Initiates | Outperform | — |
| 4 Aug 2021 | Goldman Sachs | Initiates | Neutral | — |
| 13 July 2021 | Jefferies | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for NAUT.
This page is one stock. Monday covers all of them.
NAUT appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
NAUT vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Nautilus Biotechnology, Inc. returned +0.2% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
NAUT analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 636.9×
- Price / book
- 2.3×
- EV / EBITDA
- —
Cheaper than 1% of US stocks
Cheaper than 39% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- −50.0%
- Operating margin
- —
- Net margin
- —
Higher than 2% of US stocks
- Return on equity
- −41.0%
- Return on assets
- −22.9%
- Dividend yield
- —
Higher than 24% of US stocks
Higher than 18% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Nautilus Biotechnology, Inc. has a market value of $270.0M and an enterprise value of $210.2M.
Revenue in the twelve months to 30 June 2026: $10K.
Net income over the same four quarters: −$56.5M, a −565210.0% net margin.
Diluted earnings per share, trailing twelve months: −$0.45.
Free cash flow in the twelve months to 30 June 2026: −$51.9M.
Nautilus Biotechnology, Inc. employs 128 people — $78.1 of revenue per employee.
Data provided by Twelve Data
NAUT and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at NAUT’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Nautilus Biotechnology, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about NAUT
What is the NAUT stock price forecast for 2026-2027?
The median 12-month analyst price target for Nautilus Biotechnology, Inc. is $4. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is NAUT stock a buy right now?
Of the 4 analysts covering Nautilus Biotechnology, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Nautilus Biotechnology, Inc. 70 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank NAUT?
As at 21 Nov 2026, Nautilus Biotechnology, Inc. ranks 70 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (84 of 100).
Will NAUT stock go up?
No one can know that. What the data says: the median 12-month target from 4 analysts is $4, and Ticker Nerd's factor model ranks Nautilus Biotechnology, Inc. 70 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the NAUT stock forecast for 2030?
No analyst covering Nautilus Biotechnology, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for NAUT are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $4 to $4 over the next 12 months.
How has NAUT stock performed over the past year?
Nautilus Biotechnology, Inc. returned +0.2% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Nautilus Biotechnology, Inc. do?
Nautilus Biotechnology, Inc. is a life sciences company focused on proteomics, the large-scale study of proteins and their functions. Nautilus Biotechnology develops a platform technology designed to quantify and analyze the human proteome with high resolution, combining instrumentation, consumables, software, and analysis tools into an integrated workflow.
About Nautilus Biotechnology, Inc.
Nautilus Biotechnology, Inc. is a life sciences company focused on proteomics, the large-scale study of proteins and their functions. Nautilus Biotechnology develops a platform technology designed to quantify and analyze the human proteome with high resolution, combining instrumentation, consumables, software, and analysis tools into an integrated workflow. Its current products and systems support single-molecule protein analysis and multi-cycle proteome mapping, serving research-oriented markets in biotechnology, pharmaceuticals, and academic science. The company’s platform is intended to help scientists examine protein complexity more deeply, supporting applications in biomedical research, disease biology, and drug discovery. Headquartered in Seattle, Washington, with research and development operations in San Carlos, California, Nautilus Biotechnology operates as a development-stage company in the life sciences tools segment.
CEO Mr. Sujal M. Patel · 128 employees · United States · https://www.nautilus.bio